阅读说明：本技术 12,15-二氧-α-蛇床烯在制药中的应用 (Application of 12, 15-dioxo-alpha-cnidiene in pharmacy ) 是由 王跃虎 罗吉凤 何倩 张璐 魏舒娅 夏梦媛 于 2020-06-08 设计创作，主要内容包括：本发明提供12,15-二氧-α-蛇床烯(PFC-37)在制备预防和治疗神经退行性疾病和帕金森病的药物中的应用。PFC-37对MPP<Sup>+</Sup>诱导的PC12损伤有显著的保护作用,可以用于制备预防和治疗帕金森病的药物组合物或膳食补充组合物。(The invention provides an application of 12,15-dioxo- α -cnidiene (PFC-37) in preparing a medicament for preventing and treating neurodegenerative diseases and Parkinson's disease, and the PFC-37 is used for MPP + The induced damage of the PC12 has obvious protective effect, and can be used for preparing a pharmaceutical composition or a dietary supplement composition for preventing and treating the Parkinson's disease.)

1. A pharmaceutical composition for preventing and treating neurodegenerative diseases comprises 12, 15-dioxo-alpha-cnidiene and pharmaceutically acceptable carrier.

2. A pharmaceutical composition for preventing and treating Parkinson's disease comprises 12, 15-dioxo-alpha-cnidium and pharmaceutically acceptable carrier.

3. A dietary supplement composition comprises 12, 15-dioxo-alpha-cnidiene and food adjuvants.

4.12, application of 15-dioxo-alpha-cnidiene in preparing medicines for preventing and treating neurodegenerative diseases.

5.12, 15-dioxo-alpha-cnidiene in the preparation of the medicine for preventing and treating Parkinson disease.

The technical field is as follows:

the invention belongs to the technical field of medicines, and particularly relates to application of 12, 15-dioxo-alpha-cnidiene in preparation of a medicine for preventing and treating neurodegenerative diseases.

Background art:

parkinson's disease is a common neurological disorder in the elderly. At present, levodopa replacement therapy is mainly adopted to treat the Parkinson disease, but the progress of the Parkinson disease cannot be prevented, the curative effect begins to decline after 3-5 years, not only early adverse reactions (anorexia, nausea, dizziness, mental disorder, dyskinesia and the like) are caused, but also switching phenomenon, dose-end phenomenon, dystonia and the like can be caused after long-term use [ Sunjing, bear navigation, Yaoyari, the treatment progress of the Parkinson disease. for medical review, 2020,26(2): 1157-Buza 1160,1165 ]. Therefore, the search for new therapeutic drugs and methods is a hot and difficult point of research.

1-methyl-4-phenylpyridinium ion (MPP)⁺) The induced PC12 cell damage model is a screening model of currently accepted Parkinson disease treatment drugs [ a.Delavar MR, Baghi M, Safaeinejad Z, Kiani-Esfahani A, Ghaedi K, Nasr-Esfahani MH.Differentialexpression of miR-34a, miR-141, and miR-9in MPP⁺-treated differentiated PC12cells as a model of Parkinson’s disease.Gene,2018,662:54-65；b.Lin K-H,Li C-Y,Hsu Y-M,Tsai C-H,Tsai F-J,Tang C-H,Yang J-S,Wang Z-H,Yin M-C.Oridonin,anatural diterpenoid,protected NGF-differentiated PC12 cells against MPP⁺-andkainic acid-induced injury.Food and Chemical Toxicology,2019,133:110765]. Until now, no report that sesquiterpene compound PFC-37 has activity on neurodegenerative diseases and Parkinson's disease is found in the prior art.

The invention content is as follows:

the invention utilizes MPP⁺When pharmacological active ingredients are screened by an induced PC12 cell injury model, sesquiterpene compound PFC-37 to MPP is found⁺The induced PC12 cell injury has a remarkable protective effect, and the effect of the PFC-37 is reported for the first time. The invention aims to provide application of PFC-37 in preparing a medicament for preventing and treating neurodegenerative diseases and application in preparing a medicament for preventing and treating Parkinson's disease.

In order to achieve the above purpose of the present invention, the present invention provides the following technical solutions:

a pharmaceutical composition for preventing and treating neurodegenerative diseases comprises 12, 15-dioxo-alpha-cnidiene and pharmaceutically acceptable carrier.

A pharmaceutical composition for preventing and treating Parkinson's disease comprises 12, 15-dioxo-alpha-cnidium and pharmaceutically acceptable carrier.

A dietary supplement composition comprises 12, 15-dioxo-alpha-cnidiene and food adjuvants.

Application of 12, 15-dioxo-alpha-cnidiene in preparing medicine for preventing and treating neurodegenerative diseases is provided.

Application of 12, 15-dioxo-alpha-cnidiene in preparing medicine for preventing and treating Parkinson disease is provided.

The pharmaceutically acceptable carrier as mentioned above means a pharmaceutical carrier which is conventional in the pharmaceutical field, for example, water, glucose, lactose, gum arabic and the like and other carriers suitable for use in preparing formulations in the form of solid, semisolid, liquid or aerosol. The composition may additionally contain stabilizers, thickeners, and/or coloring agents and fragrances.

The compound and the composition prepared by the pharmaceutically acceptable carrier thereof can be orally or non-orally administered, the dosage is different according to different medicines, and 1-100 mg is suitable for adults.

For oral administration, the compound is first mixed with conventional pharmaceutical adjuvants such as excipient, disintegrant, binder, lubricant, antioxidant, coating agent, colorant, aromatic agent, surfactant, etc., and made into granules, capsules, tablets, etc.: for parenteral administration, the administration may be in the form of injection, infusion solution, suppository, or the like. In preparing the above formulation, conventional formulation techniques may be used.

The compound 12, 15-dioxo-alpha-cnidiene of the present invention can be used as such or in the form of a composition for use as a pharmaceutical or nutraceutical product. The pharmaceutical composition contains 0.1-99%, preferably 0.5-90% of compound, and the balance pharmaceutically acceptable carriers and/or excipients which are nontoxic and inert to human and animals, or daily food additives and matrixes.

The specific implementation mode is as follows:

the following examples are provided to further illustrate the essence of the present invention, but are not intended to limit the present invention.